Our Team
President:
Dr. Sarode K. Pundaleeka, MD.
Medical Director of Clinical Research:
Kulumani M. Sivarajan, MD
Manager of Clinical Research:
Karen Sceniak, CCRC
ksceniak@jolietoncology.com
Clinical Research Coordinators:
815-730-3098
William D. Saroian
wsaroian@jolietoncology.com
Madelyn K. Thomas
mthomas@jolietoncology.com
Data Manager:
Jennifer Crocker
jennifercrocker@jolietoncology.com
Melissa Johnson
mjohnson@jolietoncology.com
Dipti Tambe
dtambe@jolietoncology.com
Regulatory Affairs Manager:
Joan Pufahl
joanp@jolietoncology.com
Dietitian:
Keisha Gaskin
keishag@jolietoncolgy.com
Clinical Trials - Last Update: 6/24/2011
Breast Cancer Trials
Adjuvant Breast
EOCG CTSU S0221
A Phase III Trial of Continuous Schedule AC+G vs Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
Coordinator: Karen 815-730-3033 ext: 1305
Locally Advanced or Metastatic Breast
TDM4370g
A Randomized, Multicenter, Phase III Open Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatinib in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab based therapy
Coordinator: Karen 815-730-3033 ext: 1305
Locally Recurrent or Metastatic Breast
CTSU 40502
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Coordinator: Karen 815-730-3033 ext: 1305
Metastatic Breast
GSK LPT112515
A Randomized, Phase III, Open-Label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First - or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer
Coordinator: Madelyn 815-730-3033 ext: 1257
Metastatic Breast
CTSU 70604
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Coordinator: Madelyn 815-730-3033 ext: 1257
Stage IV or IIIB Breast
CALGB 40503
CALGB 40503 Endocrine Therapy With or Without anti-VEGF Therapy: A Randomized Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer
Coordinator: Karen 815-730-3033 ext: 1305
Lung Cancer Trials
Phase I NSCLC Stage IV
ISIS 183750 CS4
A Phase1b/2 Study of Carboplatin-Paclitaxel, With or Without ISIS 183750, in Patients with Stage IV NSCLC
Coordinator: Madelyn 815-730-3033 ext: 1257
Phase II Advanced NSCLC
Daiichi U31287-A-U201
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of U3-1287 in Combination with Erlotinib in EGFR Treatment Naïve Subjects with Advanced NSCLC Who Have Progressed on at Least One Prior Chemotherapy
Coordinator: Will 815-730-3033 ext: 1252
First Line NSCLC Stage IV
Lilly H3E-US-S130
Randomized, Open-Label, Phase III Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced NSCLC of Nonsquamous Histology
Coordinator: Will 815-730-3033 ext: 1252
Fist Line NSCLC
Imclone CP15-0804
A Randomized Phase II Study of a Human Anti-PDGFRa Monoclonal Antibody (IMC-3G3) with Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients with Locally Advanced or Metastatic NSCLC
Coordinator: Will 815-730-3033 ext: 1252
Phase II SCLC
ECOG 1508
A Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer
Coordinator: Will 815-730-3033 ext: 1252
Observational NSCLC
VIEW
VeriStrat Observational Study of Patients with NSCLC
Coordinator: Will 815-730-3033 ext: 1252
Chemotherapy Induced Anemia in NSCLC
Celgene ACE-011-NSCL-001
A Single-Blind, Randomized, Phase 2A, Dose Ranging Study (Part 1) of Sotatercept (ACE-011) Therapy Followed by a Phase 2B/3, Double-Blind, Randomized, Placebo-Controlled Study (Part 2) of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects with Metastatic NSCLC Treated with First Line Platinum-Based Chemotherapeutic Regimens
Coordinator: Madelyn 815-730-3033 ext: 1257
Gastrointestinal / Genitourinary Cancer Trials
Second Line Esophageal of GE Junction
ECOG 2208
Randomized Phase II Study of Paclitaxel with or without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer
Coordinator: Karen 815-730-3033 ext: 1305
Untreated Metastatic Colorectal
CTSU 80405
A Phase III Study of FOLFIRI or FOLFOX with Bevacizumab, or Cetuximab or with the combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Coordinator: Karen 815-730-3033 ext: 1305
Prostate
ECOG 3805
ChemoHormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Coordinator: Karen 815-730-3033 ext: 1305
Metastatic Prostate
CTSU 70604
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Coordinator: Madelyn 815-730-3033 ext: 1257
Advanced Hepatocellular
CTSU 80802
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
Coordinator: Karen 815-730-3033 ext: 1305
Cervical Cancer Trials
CTSU GOG 0240
A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without NCI-Supplied Bevacizumab in Stage IVB Recurrent or Persistent Carcinoma of the Cervix
Coordinator: Karen 815-730-3033 ext :1305
Advanced Melanoma
ECOG 1608
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma
Coordinator: Will 815-730-3033 ext: 1252
MDS
ECOG 2905
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide Alone and in Combination with Epoetin Alfa in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia
Coordinator: Madelyn 815-730-3033 ext: 1257
Multiple Myeloma
CTSU 70604
A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Coordinator: Madelyn 815-730-3033 ext: 1257
Connect
Connect The Multiple Myeloma Disease Registry
Coordinator: Madelyn 815-730-3033 ext: 1257
Any Cancer – Phase I Study
AZA PH US 2007 PK 006
A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Coordinator: Karen 815-730-3033 ext: 1305
